Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | ||
By: GlobeNewswire - 06 Feb 2024 | Back to overview list |
|
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024. During the presentation, Cue Biopharma’s chief executive officer, Dan Passeri, will provide a corporate update highlighting the latest developments from its lead clinical programs, CUE-101 and CUE-102, its lead preclinical autoimmune program partnered with Ono Pharmaceutical, as well as market opportunities, competitive positioning and key forecasted value-driving 2024 milestones. A live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days. About Cue Biopharma Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit www.cuebiopharma.com and follow us on Twitter and LinkedIn. Investor Contact Media Contact |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |